Iovance Biotherapeutics

About:

Iovance Biotherapeutics is developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Website: http://www.iovance.com

Twitter/X: iovancebio

Top Investors: OrbiMed, Frazier Healthcare Partners, Quogue Capital, Broadfin Capital

Description:

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). The company is preparing for potential regulatory approval and marketing of the first autologous T-cell treatment for solid tumor cancer in the United States. Its goal is to be the leader in tumor-infiltrating lymphocyte, or TIL, therapy innovation, development, and delivery for patients with solid tumor malignancies.

Total Funding Amount:

$1.58B

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

New York, New York, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)iovance.com

Founders:

Manish Singh

Number of Employees:

501-1000

Last Funding Date:

2024-02-20

IPO Status:

Public

© 2025 bioDAO.ai